Publications by authors named "P Pisa"
The interface between science and policy is a complex space, in theory and practice, that sees the interaction of various actors and perspectives coming together to enable policy-relevant evidence to support decision-making. Early Career Researchers (ECRs) are increasingly interested in working at the science-policy interface to support evidence-informed policy, with the number of opportunities to do so increasing at national and international levels. However, there are still many challenges limiting ECRs participation, not least how such a complex space can be accessed and navigated.
View Article and Find Full Text PDFBackground: While voluntary medical male circumcision (VMMC) reduces the risk of HIV transmission by 60%, circumcision coverage falls short of the UNAIDS 90% VMMC target. We investigated whether behaviourally informed message framing increased demand for VMMC.
Setting: Adult users of the MoyaApp, a data free application in South Africa, who viewed a form designed to generate interest in VMMC during August-November 2022.
Background: The COVID-19 vaccination programme in South Africa was rolled out in February 2021 via five delivery channels- hospitals, primary healthcare (PHC), fixed, temporary, and mobile outreach channels. In this study, we estimated the financial and economic costs of the COVID-19 vaccination programme in the first year of roll out from February 2021 to January 2022 and one month prior, in one district of South Africa, the West Rand district.
Methods: Financial and economic costs were estimated from a public payer's perspective using top-down and ingredient-based costing approaches.
Background: Developing countries experience limited access to HCV laboratory tests for different reasons. Providing near to real-time HCV testing and results especially to at-risk populations including those in rural settings for timely initiation to treatment is key. Within a rural Myanmar setting, we compared HCV diagnostic detection and quantification of the GeneXpert, and Advanced Biological Laboratories UltraGene-HCV assays against the gold standard and reference method Roche real-time HCV in Myanmar.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the immunocytokine cergutuzumab amunaleukin (CEA-IL2v) and its effects on patients with advanced carcinoembryonic antigen-positive tumors, focusing on its safety, pharmacodynamics, and the issue of anti-drug antibodies (ADA).
- Researchers explored using obinutuzumab, a treatment that depletes B-cells, as a strategy to reduce ADA development while analyzing its effects in clinical trials.
- Results indicated that patients pretreated with obinutuzumab showed a significantly lower incidence of ADAs, suggesting it could be a viable approach to enhance the safety and efficacy of CEA-IL2v therapy, although some increased liver toxicity was noted in combination treatments